Home › Funds › Octagon Capital Advisors LP › AKTS

Octagon Capital Advisors LP position in AKTS

AKTIS ONCOLOGY INC · Health Care

Octagon Capital Advisors LP reported holding 713,000 shares of AKTS (AKTIS ONCOLOGY INC) in its Q3 2026 13F filing — a position valued at US$13.9M, representing 1.85% of its reported portfolio and ranking #14 among its reported holdings. Octagon Capital Advisors LP has disclosed AKTS holdings in 3 of the last 3 reported quarters, going back to Q1 2026.

Latest position (Q3 2026)713.00K sh
Reported value held$13.88M
Portfolio Weight1.85%
First reportedQ1 2026
Last changeReduce
Updated2026-11-17

Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR

How Octagon Capital Advisors LP's AKTS position evolved

Octagon Capital Advisors LP first disclosed a stake in AKTS in Q1 2026 at 960,847 shares (US$17.2M). The position peaked in Q2 2026 at 960,847 shares, worth US$31.0M. Across 3 filings, Octagon Capital Advisors LP increased the stake 0 time(s), trimmed it 1 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 713,000 shares valued at US$13.9M — a reduction of -247,847 shares quarter over quarter.. Notable position changes include a 26% trim in Q3 2026 (shares fell 17% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q1 2026 960.85K $17.19M New
Q2 2026 960.85K $30.97M Hold
Q3 2026 713.00K $13.88M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About AKTS and 13F data

AKTS (AKTIS ONCOLOGY INC) is a Health Care company. 125 other funds we track also report a position in AKTS — the largest reported positions include MPM BioImpact LLC (US$94.2M), EcoR1 Capital, LLC (US$93.9M), Blue Owl Capital Holdings LP (US$65.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding AKTS

All AKTS fund holders →

FAQ

How long has Octagon Capital Advisors LP held AKTS?

Octagon Capital Advisors LP has disclosed AKTS holdings in 3 of the last 3 reported quarters, going back to Q1 2026.

What is Octagon Capital Advisors LP's current position in AKTS?

As of Q3 2026, Octagon Capital Advisors LP holds 713.00K shares of AKTS (AKTIS ONCOLOGY INC), valued at $13.88M, representing 1.85% of its reported portfolio and ranking #14.

Has Octagon Capital Advisors LP been buying or selling AKTS?

In the latest 13F filing (Q3 2026), Octagon Capital Advisors LP reduced its position in AKTS. The position peaked in Q2 2026 at 960.85K shares.

Which other funds hold AKTS?

Other major institutional holders of AKTS include MPM BioImpact LLC, EcoR1 Capital, LLC, Blue Owl Capital Holdings LP, among 125 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.